Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT06353997 |
Title | Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients |
Recruitment | Not yet recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Providence Health & Services |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Ellison Institute of Technology (EITM) | Los Angeles | California | 90064 | United States | Details | |
Providence Portland Cancer Institute - Franz Clinic | Portland | Oregon | 97213 | United States | Details | |
Providence St. Vincent Medical Center | Portland | Oregon | 97225 | United States | Details | |
Swedish Cancer Institute | Seattle | Washington | 98104 | United States | Details |